Novel therapies and innovation for systemic sclerosis skin ulceration
- PMID: 36609122
- PMCID: PMC11671032
- DOI: 10.1016/j.berh.2022.101813
Novel therapies and innovation for systemic sclerosis skin ulceration
Abstract
Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.
Keywords: Capillaroscopy; Skin ulcer; Systemic sclerosis; Vasculopathy.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest None declared.
Figures
References
-
- Tolosa-Vilella C, Morera-Morales ML, Simeón-Aznar CP, et al. Digital ulcers and cutaneous subsets of systemic sclerosis: clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. Semin Arthritis Rheum 2016;46:200–8. 10.1016/j.semarthrit.2016.04.007. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
